Skip Nav Destination
Issues
1 January 2021
-
Cover Image
Cover Image
Nonalcoholic steatohepatitis (NASH) is a severe form of fatty liver disease characterized by inflammation, steatosis, and fibrosis and balloon degeneration from hepatocyte injury. NASH increases the risk for development of cirrhosis and hepatocellular carcinoma (HCC). Currently, there are no FDA-approved agents to reverse hepatic fibrosis and NASH. In this issue, an investigation by Gay and colleagues (starting on page 17) demonstrates a novel approach to preventing HCC by treatment with a cholecystokinin receptor antagonist, proglumide. Treatment of mice with proglumide reversed NASH; lowered hepatic inflammatory cytokines and chemokines; reduced oxidative stress; and prevented HCC. The anti-fibrotic, anti-inflammatory, and anti-proliferative effects of proglumide may provide hope for future studies to reverse hepatic fibrosis and prevent HCC. Proglumide has a broad safety profile in human subjects and could therefore easily be repurposed for prevention of HCC. The cover histological images show peri-portal fibrosis altering the microenvironment in the liver of a mouse with NASH (left panel) and prevention of these histologic changes with proglumide therapy (right panel). - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Spotlight
Commentary
Research Brief
Research Articles
Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial
David Corley Gibbs; Veronika Fedirko; John A. Baron; Elizabeth L. Barry; W. Dana Flanders; Marjorie L. McCullough; Rami Yacoub; Tapasya Raavi; Robin E. Rutherford; March E. Seabrook; Roberd M. Bostick
Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians
Courtney Macdonald; Christobel M. Saunders; Louise A. Keogh; Morgan Hunter; Danielle Mazza; Sue-Anne McLachlan; Sandra C. Jones; Stephanie Nesci; Michael L. Friedlander; John L. Hopper; Jon D. Emery; Martha Hickey; Roger L. Milne; Kelly-Anne Phillips; for the Kathleen Cuningham Consortium for Research Into Familial Breast Cancer
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.